Capri Holdings Ltd vs Enveric Biosciences Inc — how do they compare? Capri Holdings Ltd trades at $16.74 (market cap $1.91B), while Enveric Biosciences Inc trades at $1.25 (market cap $5.32M). The key difference: Capri Holdings Ltd is far larger — about 359× Enveric Biosciences Inc's market cap. Which is the better fit depends on your goals.
| CPRI | ENVB | |
|---|---|---|
Market Cap | $1.91B | $5.32M |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $17.40 |
52-Week Low | $16.68 | $1.28 |
Enterprise Value | $3.20B | $408.82K |
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $17.46, down 3.22% on the day, with a bearish technical signal from moving averages and oscillators neutral. The company reported a net loss of $1.18 billion in 2025 despite a gross profit margin of 62.26%. Recent news highlights a post-Versace turnaround focus on Michael Kors and Jimmy Choo, with management projecting fiscal 2027 growth. Analyst consensus is a buy rating with a $23.33 price target, implying significant upside from current levels.
The investment case hinges on successful execution of the two-brand strategy and return to profitability. Key risks include sustained luxury demand weakness and high debt levels, while potential rewards include valuation upside if earnings guidance is met. The stock presents a high-risk, high-reward opportunity contingent on operational improvements.
No Aura AI signal available yet.
Trailing returns across standard periods
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →